Study Shows Patients’ Acceptance of Newer Delivery Options is Minimal
You may be wondering how new delivery options of glaucoma medications should be incorporated into your practice. It might be best to start with an understanding of patient attitudes toward these novel alternatives. That was the premise behind a recent study involving nearly 200 individuals. The bottom-line finding: Among patients, acceptance of newer options is minimal at this point.
Participants—who averaged approximately 63 years of age—answered survey questions about 6 drug delivery approaches via interview at the Massachusetts Eye and Ear Glaucoma Service. Acceptance rates were as follows:
- Triple combination eye drops: 85%
- Microdose eye spray: 54%
- Drug-eluting contact lens: 31%
- Drug-eluting periocular ring insert: 43%
- Injectable subconjunctival drug insert: 32%
- Injectable anterior chamber implants: 30%
Patients with more severe glaucoma or prior glaucoma surgery were more open to newer alternatives.
Reference:
Wang B, Lin M, Nguyen Y, Turalba A. Patient attitudes toward novel glaucoma drug delivery approaches. Digit J Ophthalmol. 2018 Sep 30;24(1):16-23. doi: 10.5693/djo.01.2018.07.001.
